公开(公告)号：US20040265252A1

公开(公告)日：2004-12-30

申请号：US10821981

申请日：2004-04-12

申请人： New York University

发明人： Seth Orlow ,  Young-Tae Chang

IPC分类号： C12Q001/00 ,  A61K007/135

CPC分类号： G01N33/5044 ,  A61K8/4966 ,  A61K8/69 ,  A61K2800/70 ,  A61K2800/782 ,  A61Q19/02 ,  A61Q19/04 ,  G01N33/5008 ,  G01N33/502 ,  G01N33/6893 ,  G01N2800/207

摘要： Trisubstituted triazine compounds are screened for pigment stimulating ability or pigment inhibiting ability. Compounds which bind ATPase increase melanin in the skin or hair. Compounds found to be active are used for screening for other active compounds. Active compounds are used for increasing melanin in the skin or hair, or for decreasing melanin in the skin or hair.

摘要翻译： 筛选三取代三嗪化合物用于颜料刺激能力或色素抑制能力。 结合ATPase的化合物会增加皮肤或毛发的黑色素。 发现有活性的化合物用于筛选其他活性化合物。 活性化合物用于增加皮肤或头发中的黑色素，或用于减少皮肤或毛发中的黑色素。

公开(公告)号：US20040238379A1

公开(公告)日：2004-12-02

申请号：US10486035

申请日：2004-02-06

发明人： Stuart Lindsay ,  Trevor Thornton

IPC分类号： G01N001/00 ,  H01L029/76 ,  C12M001/00 ,  C12Q001/00

CPC分类号： C12Q1/6825 ,  G01N27/4145

摘要： A method for electronically detecting hybridization of a probe nucleic acid and a target nucleic acid is disclosed. The probe nucleic acid (130) is attached to an open semiconductor channel (110) in a back-gated field effect transistor (120). A target nucleic acid is provided on the semiconductor channel, and electrical charateristics, such as the drain to source current, are monitored for changes indicating that hybridization has occured.

摘要翻译： 公开了用于电子检测探针核酸和靶核酸杂交的方法。 探针核酸（130）连接到后门控场效应晶体管（120）中的开路半导体沟道（110）。 在半导体通道上提供靶核酸，并且监测发生杂交的变化的电特性，例如漏极 - 源极电流。

公开(公告)号：US20040238359A1

公开(公告)日：2004-12-02

申请号：US10854161

申请日：2004-05-27

申请人： MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD.

发明人： Shin Ikeda ,  Takahiro Nakaminami ,  Toshihiko Yoshioka ,  Susumu Kuwabata

IPC分类号： C12M001/00 ,  C12Q001/00 ,  C25B011/00

CPC分类号： C12Q1/004 ,  G01N27/3274

摘要： The present invention is to provide a biosensor capable of determining the concentration of a substrate with higher precision. The biosensor has a member for elimination of interfering compounds including: a redox agent which functions as an oxidant for oxidizing interfering compounds in a sample, and a carrier for immobilizing the redox agent.

摘要翻译： 本发明提供一种能够以更高精度确定基板的浓度的生物传感器。 生物传感器具有用于消除干扰化合物的成分，包括：作为用于氧化样品中的干扰化合物的氧化剂的氧化还原剂和用于固定氧化还原剂的载体。

公开(公告)号：US20040229210A1

公开(公告)日：2004-11-18

申请号：US10842908

申请日：2004-05-10

申请人： Cytokinetics, Inc.

发明人： James H. Sabry ,  Cynthia L. Adams ,  Eugeni A. Vaisberg ,  Anne M. Crompton

IPC分类号： C12Q001/00 ,  C12Q001/68 ,  G06F019/00 ,  G01N033/48 ,  G01N033/50

CPC分类号： C12M41/46 ,  B01J2219/00315 ,  B01J2219/00689 ,  B01J2219/00695 ,  B01J2219/00707 ,  B01J2219/0072 ,  C40B60/14 ,  G01N15/1475 ,  G01N2015/1477

摘要： Techniques for using information technology in therapeutics or drug discovery. In an exemplary embodiment, techniques for determining information about the properties of substances based upon information about structure of living or non-living cells exposed to substances are provided. A method according to the present invention enables researchers and/or scientists to identify promising candidates in the search for new and better medicines or treatments using, for example, a multiple biological descriptors derived from a single cell component or marker. The method employs image analysis to extract a plurality of features (e.g., cell size, distance between cells, cell population, cell type) from an image acquisition device into the database.

摘要翻译： 在治疗或药物发现中使用信息技术的技术。 在一个示例性实施例中，提供了基于关于暴露于物质的生物体或非活细胞结构的信息来确定关于物质性质的信息的技术。 根据本发明的方法使研究人员和/或科学家能够使用例如来自单个细胞成分或标记物的多种生物学描述符来鉴定寻求新的和更好的药物或治疗的有希望的候选物。 该方法采用图像分析从图像获取装置向数据库中提取多个特征（例如，小区大小，小区之间的距离，小区种群，小区类型）。

公开(公告)号：US20040229208A1

公开(公告)日：2004-11-18

申请号：US10436223

申请日：2003-05-12

发明人： M. DeZwaan Todd ,  Lining Guo ,  Keith Davis ,  Adel Zayed ,  Susanne Kjemtrup ,  Douglas Boyes ,  Brenda Warrick ,  Joseph Cameron Mitchell ,  Robert Ascenzi ,  Carol Hamilton ,  Jeffrey Woessner ,  Jorn Gorlach ,  Neil Hoffman ,  Rao Mulpuri

IPC分类号： C12Q001/00

CPC分类号： G01N33/6872 ,  C12Q1/025

摘要： The present inventors have discovered that CAX1-like Hnull/Canull2 antiporter is essential for plant growth. Specifically, the inhibition of CAX1-like Hnull/Canull2 antiporter gene expression in plant seedlings results in reduced growth and abnormal development. Thus, CAX1-like Hnull/Canull2 antiporter is useful as a target for the identification of herbicides. Accordingly, the present invention provides methods for the identification of herbicides by measuring the activity of a CAX1-like Hnull/Canull2 antiporter in the presence and absence of a compound, where an alteration of CAX1-like Hnull/Canull2 antiporter activity in the presence of the compound indicates the compound as a candidate for a herbicide.

摘要翻译： 本发明人已经发现，CAX1样H + / Ca 2+反转运蛋白对于植物生长是必需的。 具体来说，植物幼苗中CAX1样H + / Ca ++反转录酶基因表达的抑制作用减弱，生长发育异常。 因此，CAX1样H + / Ca 2+反向转运体可用作鉴定除草剂的靶标。 因此，本发明提供了通过在存在和不存在化合物的情况下测定CAX1样H + / Ca 2+反转录酶的活性来鉴定除草剂的方法，其中CAX1样H + / Ca ++ 2>在化合物存在下的反转运体活性表示该化合物作为除草剂的候选物。

公开(公告)号：US20040204430A1

公开(公告)日：2004-10-14

申请号：US09828413

申请日：2001-04-06

发明人： Robert H. DeBellis ,  Bernard F. Erlanger

IPC分类号： A61K031/522 ,  A61K031/52 ,  C12Q001/00

CPC分类号： A61K31/52 ,  A61K31/522 ,  Y10S514/815

摘要： This invention provides a method of treating a subject afflicted with sickle cell disease which comprises administering to the subject an amount of an antiviral agent effective to inhibit sickling of a cell in the subject, so as to thereby treat the subject afflicted with sickle cell disease. This invention also provides a method of inhibiting polymerization of hemoglobin which comprises contacting the hemoglobin with an amount of an antiviral agent effective to inhibit polymerization of the hemoglobin, so as to thereby inhibit polymerization of the hemoglobin. This invention further provides a method of inhibiting sickling of a cell which comprises contacting the cell with an amount of an antiviral agent effective to inhibit polymerization of hemoglobin in the cell, so as to thereby inhibit sickling of the cell.

摘要翻译： 本发明提供一种治疗患有镰状细胞病的受试者的方法，其包括向受试者施用一定量的有效抑制受试者中细胞镰状的抗病毒剂，从而治疗患有镰状细胞病的受试者。 本发明还提供一种抑制血红蛋白聚合的方法，其包括使血红蛋白与一定量的有效抑制血红蛋白聚合的抗病毒剂接触，从而抑制血红蛋白的聚合。 本发明还提供一种抑制细胞镰刀菌的方法，其包括使细胞与一定量的有效抑制细胞中血红蛋白聚合的抗病毒剂接触，从而抑制细胞的镰状。

公开(公告)号：US20040197768A1

公开(公告)日：2004-10-07

申请号：US10754711

申请日：2004-01-12

申请人： NATIONAL HEALTH LABORATORY SERVICE

发明人： Deborah Kim Glencross

IPC分类号： C12Q001/00

CPC分类号： G01N15/1468 ,  G01N15/1459 ,  G01N2015/008 ,  G01N2015/1006 ,  G01N2015/1037 ,  G01N2015/1402 ,  G01N2015/1477 ,  G01N2015/1486 ,  G01N2015/149

摘要： The invention provides a method of enumerating the number of cells of a cell type in a cell sample by (a) counting the white blood cells in the cell sample to obtain the white blood cell population of the sample; (b) determining the proportion or percentage of the cells of the cell type in the white blood cell population in the sample; and (c) calculating the number of cells of the cell type in the sample. The cell type may be a lymphocyte sub-set selected from the group comprising CD4null lymphocytes, CD 45 cells, CD19 cells, CD16 and CD56 positive cells, CD8 cells, CD3 cells or any combination thereof. The method is particularly useful in monitoring the immune status of a patient infected with HIV or other immune deficiency state or disease or condition where CD4null lymphocytes or CD4null T cells are monitored or counted.

摘要翻译： 本发明提供一种通过（a）计数细胞样品中的白细胞以获得样品的白血细胞群体来列举细胞样品中细胞类型细胞数的方法; （b）确定样品中白细胞群中细胞类型细胞的比例或百分数; 和（c）计算样品中细胞类型的细胞数。 细胞类型可以是选自CD4 +淋巴细胞，CD45细胞，CD19细胞，CD16和CD56阳性细胞，CD8细胞，CD3细胞或其任何组合的淋巴细胞亚组。 该方法特别可用于监测感染HIV或其他免疫缺陷状态或疾病或病症的患者的免疫状态，其中CD4 +淋巴细胞或CD4 + T细胞被监测或计数。

公开(公告)号：US20040197766A1

公开(公告)日：2004-10-07

申请号：US10186499

申请日：2002-07-01

申请人： Millennium Pharmaceuticals, Inc.

发明人： Wei Gu ,  Liang-Ping Weng

IPC分类号： C12Q001/00 ,  C12Q001/68

CPC分类号： A61K48/00 ,  A01K2217/05 ,  A01K2217/075 ,  A61K38/00 ,  C07K14/705

摘要： The invention relates to methods and compositions for the treatment and diagnosis of body weight disorders, including, but not limited to, obesity, overweight, anorexia, cachexia, insulin resistance, and diabetes. The invention further provides methods for identifying a compound capable of treating a body weight disorder. In addition, the invention provides a method for treating a subject having a body weight disorder characterized by aberrant 58128 polypeptide activity or aberrant 58128 nucleic acid expression. In another aspect, the invention provides methods for modulating 58128 polypeptide activity or 58128 expression in a subject.

摘要翻译： 本发明涉及用于治疗和诊断体重障碍的方法和组合物，包括但不限于肥胖，超重，厌食，恶病质，胰岛素抵抗和糖尿病。 本发明还提供了鉴定能够治疗体重障碍的化合物的方法。 此外，本发明提供了一种治疗身体重量障碍的受试者的方法，其特征在于异常58128多肽活性或异常58128核酸表达。 另一方面，本发明提供调节受试者中58128多肽活性或58128表达的方法。

公开(公告)号：US20040185487A1

公开(公告)日：2004-09-23

申请号：US10794282

申请日：2004-03-03

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Charles H. Halsted ,  Angela M. Devlin

IPC分类号： C12Q001/00 ,  C12Q001/68

CPC分类号： C12Q1/6883 ,  C12Q1/6886 ,  C12Q2600/156

摘要： The invention provides methods for detecting mutations in the human GCPII gene which affect the ability of an individual to hydrolyze terminal glutamates from dietary folates. Such individuals are at increased risk for conditions associated with hyperhomocyteinemia, in particular, cardiovascular disease, colon cancer, and altered cognition in the elderly, including Alzheimer's disease. In addition, pregnant women with low folate status are at increased risk of bearing children with neural tube defects and congenital heart defects. Individuals with these mutations can be screened and treated with supplementation of their diet with folic acid.

摘要翻译： 本发明提供了检测人类GCPII基因突变的方法，其影响个体从饮食叶酸水解末端谷氨酸的能力。 这些个体对与高蛋白血症特别是心血管疾病，结肠癌和老年人认知改变（包括阿尔茨海默病）有关的病症的风险增加。 此外，具有低叶酸状态的孕妇具有承受神经管缺陷和先天性心脏缺陷的儿童的风险增加。 具有这些突变的个体可以筛选并用叶酸补充他们的饮食来治疗。

公开(公告)号：US20040185432A1

公开(公告)日：2004-09-23

申请号：US10815747

申请日：2004-04-02

申请人： BioImage A/S

发明人： Bernard Robert Terry ,  Kurt Marshall Scudder ,  Per Olaf Gunnar Arkhammer ,  Ole Thastrup

IPC分类号： C12Q001/00 ,  C12Q001/68 ,  G01N033/53

CPC分类号： G01N33/502 ,  G01N33/5008

摘要： A method and apparatus for screening an array of test compounds for bioactivity by contacting an array of test compounds with a detector layer capable of detecting bioactivity, and detecting a detector layer response. The detector layer is comprised of physiologically viable cells. The method and apparatus allow a large number of test compounds to be simultaneously assayed in parallel without the need for complex fluidic devices.